TYSABRI Global Observational Program in Safety
Completed
Conditions studied: Multiple Sclerosis
In brief
The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).
Key facts
- Study ID
- NCT00477113
- Run by
- Biogen
- People needed
- 2207
- Starts
- 2007-01-01
- Expected to finish
- 2015-05-01
- Last updated by the study team
- 2015-06-22
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- There may be mulitple sites in this clinical trial. Contact United BioSource Corporation — Kansas City, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.